Nurix Therapeutics, Inc. NRIX Operating Lease Liability Payments - 2024 (Lessee)

Operating Lease Liability Payments - 2024 (Lessee) at other companies

Nuvation BioNUVB

——

BridgeBio PharmaBBIO

——

Neurocrine BiosciencesNBIX

——

BioCryst PharmaceuticalsBCRX

——

Mirum Pharmaceuticals, Inc.MIRM

——

Other financials

Income statement

See full

Revenue$6.3M-66.1%

Operating income-$92.5M-47.1%

Net income-$87.2M-54.7%

EPS (diluted)-$0.79-17.9%

Balance sheet

See full

Cash & equivalents$72.2M-6.1%

Total debt$58.7M+120%

Total equity$480.9M0.0%

Total assets$636.1M+3.4%

Cash flow

See full

Operating cash flow-$71.9M-17.7%

CapEx$1.0M-70.0%

Free cash flow-$73.0M-13.0%

Valuation

See full

Market cap$1.95B+40.1%

Enterprise value$1.94B+45.1%

P/S27.2×+2.5×

Profitability

See full

Operating margin-439.3%+35.3pp

Net margin-411.4%+52.7pp

FCF margin-378.7%+24.1pp

Returns & leverage

See full

Return on equity-61.4%-2.5pp

Debt / equity0.1×+0.1×

Current ratio6×-0.3×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nurix Therapeutics, Inc.'s operating lease liability payments - 2024 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nurix Therapeutics, Inc.'s operating lease liability payments - 2024 (lessee)?: Nurix Therapeutics, Inc. (NRIX) reported operating lease liability payments - 2024 (lessee) of $9.18M in Q3 2025.